Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ (The Korean Society Nonclinical Study)-KSNS

ÇмúÇà»ç

·Î±×ÀÎ ¾ÆÀ̵ð ±â¾ï
 
ÇмúÇà»ç¸ñ·Ï Home > ÇмúÇà»ç > ÇмúÇà»ç¸ñ·Ï
Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ 2015³â Á¦27Â÷ Workshop °³ÃÖ °øÁö
ÀÛ¼ºÀÚ °ü¸®ÀÚ email http://www.nonclinical.or.kr
Date2015³â 03¿ù 03ÀÏ 10:26Hits5919
÷ºÎÆÄÀÏ ¡Ø ÇöÀç DB¿¡´Â ÆÄÀÏÁ¤º¸°¡ ÀÖÀ¸³ª, FTP »ó¿¡ ÆÄÀÏÀÌ Á¸ÀçÇÏÁö ¾Ê½À´Ï´Ù.
Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ 2015³â Á¦27Â÷ Workshop °³ÃÖ ¾È³»

¡á Çà»ç°³¿ä

Çà»ç¸í Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ 2015³â Á¦27Â÷ Workshop
ÁÖÁ¦ "Translational approaches from nonclinical studies to clinical implementation (°¡Äª)"
ÀϽà 2015³â 5¿ù 20(¼ö)
Àå¼Ò °æ±âÁß¼Ò±â¾÷Áö¿ø¼¾ÅÍ "±¤±³È¦" (1Ãþ) (ÁÖ¼Ò : °æ±âµµ ¼ö¿ø½Ã ¿µÅ뱸 ±¤±³·Î 107)
´Ù¿î·Îµå °ø¹® - Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ Á¦27Â÷ ¿öÅ©¼¥ °³Ã־ȳ»
¹®ÀÇ KSNS »ç¹«±¹ : Tel. 031) 706-2995 / E-mail. ksns@nonclinical.or.kr / ´ã´çÀÚ. Áö¼º¹Ì ¼±»ý´Ô

¡á µî·Ï ¾È³»

- »çÀüµî·Ï ¾È³»
Çà»ç¸í ¤ý 2015 Çѱ¹ºñÀӻ󿬱¸È¸ Á¦27Â÷ ¿öÅ©¼¥
µî·Ï±â°£ ¤ý2015³â 4¿ù 29ÀÏ(È­) 09½Ã ~ 5¿ù 18ÀÏ (¿ù) 18½Ã
µî·Ï¹æ¹ý ¤ý ¿¬±¸È¸ ȨÆäÀÌÁö (www.nonclinical.or.kr) ÇмúÇà»ç > »çÀüµî·Ï ¸Þ´º ÀÌ¿ë
¤ý ºñȸ¿øÀº ȸ¿ø°¡ÀÔ ÈÄ, »çÀüµî·ÏÀÌ °¡´ÉÇÕ´Ï´Ù.

- µî·Ïºñ
µî·Ïºñ ±¸ºÐ »çÀüµî·Ï ÇöÀåµî·Ï
Á¤È¸¿ø 50,000 ¿ø 70,000 ¿ø
Çлýȸ¿ø 20,000 ¿ø 40,000 ¿ø
  • »çÀüµî·Ïºñ : ÀÚ·áÁý, ¼ö·áÁõ, ½Äºñ Æ÷ÇÔ
  • ¼¼±Ý°è»ê¼­ ¹ß±Þ(ÀÔ±ÝÀÏ ±âÁØ 1ȸ ¹ß±Þ)ÀÌ ÇÊ¿äÇÒ °æ¿ì, ¿Â¶óÀÎ µî·Ï¶§ ¼¼±Ý°è»ê¼­ ¹ßÇàÇà¿©ºÎ¸¦ üũÇϽðí, »ç¾÷ÀÚµî·ÏÁõ »çº»À» ¹Ýµå½Ã ÷ºÎ
  • ÇöÀåµî·Ï ¹× Çлýµî·ÏÀÇ °æ¿ì, ¼¼±Ý°è»ê¼­ ¹ß±Þ ºÒ°¡, ¿¬±¸È¸ ÀÚü ¿µ¼öÁõ ¹ß±Þ

- ¹«ÅëÀåÀÔ±Ý (°èÁÂÀÌü)
ÀԱݰèÁ ¤ý ¿ì¸®ÀºÇà 1005-101-920320 ¢ß Å¥º£½ºÆ®ÄÁ¼³ÆÃ ºñÀӻ󿬱¸È¸
ÀԱݸ¶°¨ ¤ý ~ 2015³â 5¿ù 18ÀÏ (¿ù) 18½Ã ±îÁö
  • ÀԱݽà ¹Ýµå½Ã "¼Ò¼Ó/¼º¸í" À» ±âÀÔÇϼ¼¿ä.
  • ¹«ÅëÀå ÀÔ±Ý(°èÁÂÀÌü)ÀÌü ÈÄ, »ç¹«±¹¿¡¼­ ÀÔ±ÝÀ» È®ÀÎÇÏ´Â ½Ã°£ÀÌ 1ÀÏÁ¤µµ ¼Ò¿ä µË´Ï´Ù.
  • ½Å¿ëÄ«µå °áÁ¦´Â ºÒ°¡´É ÇÕ´Ï´Ù.
  • ±âŸ µî·Ï °ü·Ã ¹®ÀÇ»çÇ×Àº Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ »ç¹«±¹À¸·Î ¹®ÀÇÇÏ¿© Áֽñ⠹ٶø´Ï´Ù.
    Tel. 031-706-2995, E-mail ksns@nonclinical.or.kr, °íÁ¾È­




¡á ÇÁ·Î±×·¥ ¾È³» (Draft / Ver.2015.05.01)

Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸(KSNS) Á¦27Â÷ WORKSHOP Program (V2.0)

  1. ÁÖÁ¦: Translational approaches from nonclinical studies to clinical implementation
  2. ÀϽÃ: 2015³â 5¿ù 20ÀÏ (¼ö¿äÀÏ) 09:20 ~ 17:30
  3. Àå¼Ò: °æ±âÁß¼Ò±â¾÷Á¾ÇÕÁö¿ø¼¾ÅÍ(GSBC, ±¤±³Å×Å©³ë¹ë¸®³», °æ±âµµ ¼ö¿ø½Ã ¿µÅ뱸 ±¤±³·Î 107)

  2015³â 5¿ù 20ÀÏ (¼ö)
Time PROGRAM
09:20-09:50 Registration
09:50-10:00 Opening (±èµ¿È¯ ȸÀå)
Session 1 Drug discovery and Development : Practice and Perspective
(
ÁÂÀå : ¾ÈÀü¼ºÆò°¡¿¬±¸¼Ò Â÷½Å¿ì ¹Ú»ç)
10:00-10:40 ºñÀÓ»ó½ÃÇè °á°ú·ÎºÎÅÍ ÀÓ»ó ÃÊȸ¿ë·® ¼³Á¤ : FDA and EMEA guideline (°Ç¾ç´ë, ±èµ¿È¯ ±³¼ö)
10:40-11:20 TEW-7197, An ALK5 inhibitor: From non-clinical studies to US FDA IND (¸ÞµåÆÑÅä, ÇÏÀÏÈ£ ¹Ú»ç)
11:20-12:00 Pharmacokinetics with biologic - An industry prospective into best practices for the development and validation of ligand binding assays to support biosimilar programs (Dr. Rashell Kinard, MPI)
12:00-12:45 Luncheon symposium: ¿À¼Û÷º¹´ÜÁöÀÇ ±¹°¡Àû ½Å¾à°³¹ßÁö¿øÃ¼°è (Sponsor: ¿À¼Û÷´ÜÀÇ·á»ê¾÷ÁøÈïÀç´Ü)
12:45-13:30 Booth Exhibition & Coffee Break
Session 2 µ¶¼ººÐ°ú
(ÁÂÀå : ÇÑÈ­, °í¿ì¼® ¹Ú»ç)

Issues & Solutions in Toxicity Studies
¾àµ¿·ÂÇкаú
(ÁÂÀå : µ¿¾Æ ST, ½ÉÇöÁÖ ¹Ú»ç)

PK studies related with clinical dose
¾àÈ¿¾à¸®ºÐ°ú
(ÁÂÀå : Çö´ë¾àǰ, ±è´ëÈÆ ¹Ú»ç)

Efficacy Evaluation for Key Therapeutic Areas
13:30-14:10 Current Trends in Genetic Toxicology Testing
(KIT, ±èÁö¿µ ¼±ÀÓ¿¬±¸¿ø)
ºñÀÓ»ó ÀÚ·áÀÇ ¸ðµ¨¸µ/½Ã¹Ä·¹À̼ÇÀ» ÅëÇÑ FIH ¿ë·® ¿¹ÃøÀÇ »ç·Ê
(ÀÓµ¿¼® ±³¼ö, °¡Å縯´ë)
Anti-diabetic effect of amorphastilbol by increasing insulin sensitivity
(±è¿ë±â ±³¼ö, ¼÷¸í¿©´ë)
14:10-14:50 º¹ÇÕÁ¦ µ¶¼º½ÃÇèÀÇ À̽´ ¹×
Àü·«Àû solution
(À̱ÔÇ× ¹Ú»ç, Çѹ̾àǰ)
ÀüÀÓ»ó ½ÃÇè °á°ú¸¦ ÀÌ¿ëÇÑ Human efficacious dose projection
(Á¤¼ö¿ë ¼ö¼®¿¬±¸¿ø, À¯ÇѾçÇà)

¾ËÃ÷ÇÏÀÌ¸Ó °ü·Ã ¾à¹° °³¹ßÀ» À§ÇÑ ºñÀÓ»ó Á¢±Ù¹ý
(Å©·Î¿£¸®¼­Ä¡ Áø½ÂÇÏ ¹Ú»ç)

14:50-15:30 »ýü¿µ»ó ¹× ¹Ì¼¼¼ö¼úÀ» ÅëÇÑ ½Å¾à°³¹ß¿¡ ÀÖ¾î À¯È¿¼º/¾ÈÀü¼º Æò°¡ (±è»ó±Õ ¹Ú»ç, ´ë±¸°æºÏ÷º¹´ÜÁö) Optimal clinical dose-finding strategies: Translational preclinical PK, PD, and efficacy analysis of orally selective EGFR mutant inhibitor
(ÀÌ¿µ¹Ì ¹Ú»ç, Çѹ̾àǰ)

A biomarker as a necessary factor in development of targeted agent for cancer treatment
(Áøµ¿ÈÆ ±³¼ö, ¿ï»êÀÇ´ë)

15:30-16:00 Booth Exhibition & Coffee Break
Session 3 Drug discovery and Development: Case Studies (ÁÂÀå : ÃÖ¿¬½Ä ±³¼ö, Çѱ¹Æú¸®ÅØ´ëÇÐ)
16:00-16:40 Â÷¼¼´ë ÁøÅë¼Ò¿°Á¦ ¾Æ¼¿·º½ºÀÇ °³¹ß (Å©¸®½ºÅ»Áö³ë¹Í½º, ³ë¼º±¸ ¹Ú»ç)
16:40-17:20 A novel therapeutic DNA vaccine against persistent human papillomavirus infection (Á¦³Ø½Å, ÁøÇöŹ ¹Ú»ç)
17:20-17:30 Closing (ÀÌ»óÈ£ ºÎȸÀå)

# »ó±â ÇÁ·Î±×·¥Àº ¿¬ÀÚ µîÀÇ »çÁ¤À¸·Î º¯µ¿ ¼ö ÀÖ½À´Ï´Ù.

¡á °æ±âÁß¼Ò±â¾÷Á¾ÇÕÁö¿ø¼¾ÅÍ "±¤±³È¦" ã¾Æ¿À½Ã´Â ±æ

ÁÖ¼Ò °æ±âµµ ¼ö¿ø½Ã ¿µÅ뱸 ±¤±³·Î 107, °æ±âÁß¼Ò±â¾÷Á¾ÇÕÁö¿ø¼¾ÅÍ "±¤±³È¦" (1Ãþ)
- [³×À̹ö Áöµµ]·Î À§Ä¡ È®ÀÎ ¹× ±³Åë Âü°í :
±³ÅëÆí ¾È³» °æ±âÁß¼Ò±â¾÷Á¾ÇÕÁö¿ø¼¾ÅÍ È¨ÆäÀÌÁö ³» [ ¿À½Ã´Â ±æ ] ¸Þ´º Âü°í :




Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ 2015³â Á¦27Â÷ Workshop ÇùÂù ¸ðÁý
(·±Ãµ¼¼¹Ì³ª, ºÎ½º, ±¤°í)

1. ±Í»çÀÇ ¹«±ÃÇÑ ¹ßÀüÀ» ±â¿øÇÏ¿À¸ç, Ç×»ó ÀúÈñ Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸¿¡ °ü½ÉÀ» °¡Á®Áֽɿ¡ ±íÀÌ °¨»çµå¸³´Ï´Ù.

2. Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸¿¡¼­ ÁÖ°üÇÏ´Â Á¦27Â÷ WorkshopÀ» 2015³â 05¿ù 20ÀÏ(¼ö) °æ±â Áß¼Ò±â¾÷ Á¾ÇÕÁö¿ø¼¾ÅÍ ±¤±³È¦¿¡¼­ "Translational approaches from nonclinical studies to clinical implementation (°¡Äª)" À̶õ ÁÖÁ¦·Î °³ÃÖÇϰíÀÚ ÇÕ´Ï´Ù. ¼º°øÀûÀÎ ÇмúÇà»ç °³ÃÖ¸¦ À§ÇÏ¿© ±Í ±â°üÀÇ ºÎ½º ¹× ±¤°í ÇùÂùÀ» ¿äû µå¸®¿À´Ï Àû±ØÀûÀÎ Âü¿© ºÎŹ µå¸³´Ï´Ù. ¶ÇÇÑ, ±Í»çÀÇ °ü°èÀÚ ºÐµé²²¼­µµ ÇмúÇà»ç¿¡ Âü¼®ÇÏ½Ã¾î ±Í»ç¿¡ µµ¿òÀÌ µÉ human networking°ú Çмú±³·ù¸¦ ÇÒ ¼ö ÀÖµµ·Ï ÇùÁ¶ÇÏ¿© ÁÖ½Ã¸é °¨»çÇϰڽÀ´Ï´Ù.

- ´Ù À½ -

Çà»ç¸í Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ 2015³â Á¦27Â÷ Workshop
ÁÖÁ¦ "Translational approaches from nonclinical studies to clinical implementation (°¡Äª)"
ÀϽà 2015³â 05¿ù 20(¼ö) 09:20~17:30
Àå¼Ò °æ±âÁß¼Ò±â¾÷Á¾ÇÕÁö¿ø¼¾ÅÍ ±¤±³È¦, Çõ½Å½Ç, Èñ¸Á½Ç
ÇùÂù³»¿ë 1) ·±Ãµ¼¼¹Ì³ª(ºÎ½º/±¤°í ¹× µµ½Ã¶ôºñ¿ë Æ÷ÇÔ): \5,000,000 (VATº°µµ) / Çмú´ëȸ Âü°¡ºñ 5¸í ¹«·á
* 20(¼ö) Á¡½É½Ã°£(12:00~13:00) / ½Ä»çÀοøÀº »çÀüµî·Ï ¸¶°¨ ÈÄ Å뺸 (2014³â ¾à 180¸í)

2) ºÎ½º(±¤°í Æ÷ÇÔ): \2,000,000 (VATº°µµ)
* ÇùÂù¾÷ü °ü°èÀÚ 2¸í¿¡ ÇÑÇÏ¿© Çмú´ëȸ Âü°¡ºñ ¹«·á
* ¼Ò¿¬È¸Àå¿¡ 2X2 ¹ÌÅÍ Å©±âÀÇ ºÎ½º ¼³Ä¡ °¡´É /ºÎ½º ´ç Å×À̺í 1°³ ¹× ÀÇÀÚ 2°³ Á¦°ø
* ºÎ½º¼³Ä¡¿Í °ü·Ã À¯ÀÇ»çÇ× ¹× Áغñ»çÇ×Àº Ãß ÈÄ °øÁö

3) ±¤°í(ÀÚ·áÁý): \1,000,000 (VATº°µµ) / Çмú´ëȸ Âü°¡ºñ 1¸í ¹«·á
¸¶°¨ÀÏÀÚ 2015³â 04¿ù 30ÀÏ(¸ñ)
* ·±Ãµ¼¼¹Ì³ª ¹× ºÎ½ºÀÇ °æ¿ì, ¼±Âø¼ø ¸¶°¨ (¼³Ä¡ À§Ä¡´Â º°µµ·Î Ãß÷ÁøÇà/Ãß÷ÀÏÁ¤ ÃßÈÄ Å뺸)
ÀԱݰèÁ ¿ì¸®ÀºÇà 1005-101-920320 ¢ßÅ¥º£½ºÆ®ÄÁ¼³ÆÃºñÀӻ󿬱¸È¸
°ü·Ã°ø¹® °ø¹® ´Ù¿î·Îµå :
Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ 2015 Á¦27Â÷ Workshop ÇùÂù ¸ðÁý (·±Ãµ¼¼¹Ì³ª, ºÎ½º, ±¤°í) 
¹®ÀÇ ÀÌ ¿Ü ±¤°íÇùÂù°ú °ü·ÃÇØ ±Ã±ÝÇϽŠ»çÇ×Àº KSNS »ç¹«±¹À¸·Î ¹®ÀÇÇÏ¿© Áֽñ⠹ٶø´Ï´Ù.
KSNS »ç¹«±¹ : Tel. 031) 706-2995 / E-mail. ksns@nonclinical.or.kr / ´ã´çÀÚ. °íÁ¾È­




List
°³ÀÎÁ¤º¸Ãë±Þ¹æÄ§
¢ßµå¸²¹ÙÀÌ¿À (»ç¾÷ÀÚµî·Ï¹øÈ£ : 320-88-00843, ´ëÇ¥ : ±è»ó¿ì)
Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ (The Korean Society Nonclinical Study)
(¿ì)446-982 °æ±âµµ ¿ëÀνà ±âÈﱸ Èï´öÁß¾Ó·Î 120 U-TOWER 1411È£
Tel : 031-702-9123 , Fax : 031-213-9125, E-Mail : ksns@nonclinical.or.kr
Copyright & "The Korean Society Nonclinical Study". Website development and maintenance: "Expedition". All Rights Reserved.